Implicit Bias, Nurse's Role, Stigma, Social
Conditions
Brief summary
The goal of this pilot clinical trial is to evaluate the feasibility and limited effectiveness of a digital, arts-based educational intervention addressing nurse stigma towards perinatal substance use. The main questions it aims to answer are: * What is the the feasibility of delivering the training through an asynchronous, web-based platform? * What is the limited effectiveness of the program on nurse stigma towards perinatal substance use? Participants will access and complete the training, including completion of a perinatal substance use stigma scale at baseline, immediately post, and 1-2 months month later. Participants will also be invited to participate in an interview. Researchers will compare the intervention and control groups to see if the training reduces nurse stigma towards perinatal substance use.
Interventions
OTHERArtSpective
ArtSpective is an interactive, educational program that uses art and museum-based pedagogy. The intervention is delivered asynchronously using a web-based platform. Participants engage with artwork, watch short educational videos, and read short clinical vignettes. After completing the program, participants receive a certificate of completion.
Sponsors
University of Michigan
National Institute on Drug Abuse (NIDA)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 years or older * Licensed as a registered nurse * Works at least part time * Works on a labor, postpartum, nursery, neonatal intensive care, or pediatric unit in one of the participating hospitals
Exclusion criteria
* Works as per diem or agency nurse * Not employed by a participating hospital * Not a perinatal/pediatric nurse
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Nurse Stigma Toward Perinatal Substance Use | Baseline (Phase 1a); immediately post intervention (Site 1) or 7-30 days post baseline (Site 2) (Phase 1b); immediately post (Site 2) or 30 days post intervention (Site 1) (Phase 2); 30 days post (Site 2) or 60 days post intervention (Site 1) (Phase 3) | Negative or stigmatizing attitudes and/or beliefs registered nurses have towards perinatal substance use; measured using the Modified Attitudes About Drug Use in Pregnancy Scale. Total scores range between 1 and 5, with scores closer to 1 associated with a more positive outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Acceptability | immediately post intervention (Site 1= Phase 1b; Site 2 = Phase 2) | The level of satisfaction participants have towards the intervention; measured using an adapted version of the Abbreviated Acceptability Rating Profile. Total scores range from 1 to 5 with scores closer to 5 representing a more positive outcome. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited from two hospitals in July 2024. The study aimed to recruit up to 75 participants from each hospital.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 36 years STANDARD_DEVIATION 10.07 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 47 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Modified Attitudes About Drug Use in Pregnancy Scale | 2.91 units on a scale STANDARD_DEVIATION 0.59 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 95 Participants |
| Sex: Female, Male Female | 52 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 47 | 0 / 52 |
| other Total, other adverse events | 0 / 47 | 0 / 52 |
| serious Total, serious adverse events | 0 / 47 | 0 / 52 |
Outcome results
None listed